Seeking Alpha

A new and potential blockbuster drug from Bayer (BAYRY.PK +4%), Regorafenib, could significantly...

A new and potential blockbuster drug from Bayer (BAYRY.PK +4%), Regorafenib, could significantly increase the survival prospects of people with gastrointestinal cancer, according to new research published in U.K. medical journal The Lancet. The study also showed survival rates for patients with metastatic bowel cancer improved by taking the drug as well, though not as significantly. Bayer has tagged Regorafenib as one of its most significant new pipeline products.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs